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Abstract Nondeletional hereditary persistence of fetal he-
moglobin (nd-HPFH), a rare hereditary condition resulting in
elevated levels of fetal hemoglobin (Hb F) in adults, is
associated with promoter mutations in the human fetal globin
(HBG1 and HBG2) genes. In this paper, we report a novel
type of nd-HPFH due to a HBG2 gene promoter mutation
(HBG2:g.-109G>T). This mutation, located at the 3′ end of
the HBG2 distal CCAAT box, was initially identified in an
adult female subject of Central Greek origin and results in
elevated Hb F levels (4.1%) and significantly increased Gγ-
globin chain production (79.2%). Family studies and DNA
analysis revealed that the HBG2:g.-109G>T mutation is also
found in the family members in compound heterozygosity
with the HBG2:g.-158C>T single nucleotide polymorphism
or the silent HBB:g.-101C>T β-thalassemia mutation, result-
ing in the latter case in significantly elevated Hb F levels
(14.3%). Electrophoretic mobility shift analysis revealed that
the HBG2:g.-109G>T mutation abolishes a transcription
factor binding site, consistent with previous observations
using DNA footprinting analysis, suggesting that guanine at
position HBG2/1:g.-109 is critical for NF-E3 binding. These
data suggest that the HBG2:g-109G>T mutation has a func-
tional role in increasing HBG2 transcription and is responsi-
ble for the HPFH phenotype observed in our index cases.
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Introduction
Hereditary persistence of fetal hemoglobin (HPFH) is a
genetic condition characterized by persistent elevated levels
of fetal hemoglobin (Hb F) in the adult erythroid stage [1].
HPFH heterozygotes have a normal clinical phenotype and
hematological indices, except for the lower levels of
hemoglobin A2 (Hb A2) that constitutes the hallmark
of HPFH. The reason for that is the increased frequency of
interactions between the locus control region (LCR) and the
mutated γ-globin gene promoter compared to the normal
situation. Subsequently, this shifts the transcriptional balance
in favor to the otherwise silent, fetal globin genes, resulting
in lower HBD gene transcription and Hb A2 levels [2].
The various forms of HPFH are distinguished into two
main categories, namely, deletional and nondeletional HPFH
(nd-HPFH), due to large deletions 3′ to the fetal globin genes
or nucleotide substitutions in the fetal globin gene promoters,
respectively [3]. The current explanation for the functional
role of the latter HPFH category is the destabilization of a yet
unknown silencing protein complex that permits LCR–gene
interactions and recruitment of the basal transcriptional
machinery to the mutated γ-globin gene promoter, leading
to reactivation of fetal globin gene transcription [4].
To date, there are few γ-globin promoter mutations,
leading to nd-HPFH clustered on or in close proximity to γ-
globin gene cis-regulatory elements [5]. The most important
nd-HPFH is the Greek type (HBG1:g.-117G>A [6]), whose
functional role is also demonstrated in transgenic mice [7].
This mutation is located at the 5′ end of the distal γ-globin
gene CCAAT box where important erythroid-specific tran-
scription factors bind. Other mutations cluster approximately
200 bp upstream to the γ-globin genes transcription initiation
site where a GC-rich region is located. Although clinically
silent, the mutations leading to nd-HPFH provide valuable
insights into the transcriptional regulation of the human fetal
globin genes, which in turn can enable design of novel
strategies for β-thalassemia therapeutics.
In this communication, we report the Hellenic type of nd-
HPFH due to a novel G>T transversion in the HBG2 gene
promoter, located at the 3′ end of the distal HBG2 CCAAT box.
Materials and methods
Case selection
For the needs of this study, the mother and two sisters of
the index case were also recruited. Unfortunately, the father
of the index case was deceased, but, nevertheless, his sister
was available for study (Fig. 1a). Also, 31 heterozygotes for
the silent HBB:g.-101C>T β-thalassemia mutation have
been included (Table 1), as well as 89 normal (non-
thalassemic) individuals. The study was previously ap-
proved by the hospital’s ethics committee.
Hemoglobin studies
Blood samples were collected, with consent, in vacutainers
with ethylenediaminetetraacetic acid as anticoagulant. Hema-
tological indices were measured with an automated cell
counter and Hb A2 and Hb F levels were quantitated, using
cation exchange high-performance liquid chromatography
(HPLC; VARIANT™, BioRad, Hercules, CA, USA). Globin
chain quantitation was performed using reverse-phase
HPLC, using the RP-18 column (Pharmacia, Uppsala,
Sweden).
DNA analysis
Total genomic DNA isolation and γ-globin gene pro-
moters’ amplification was done as previously described
[8]. Mutation screening in the human γ-globin gene
promoters was performed using denaturing gradient gel
electrophoresis (DGGE) with a 40–70% linear gradient of
denaturing agents (urea and formamide; 100% denaturant:
7 M urea, 40% formamide), as previously described [9].
HBB and HBD gene mutation screening was done as
described in Losekoot and coworkers [10] and Papadakis
and coworkers [11], respectively. Automated DNA se-
quencing was performed directly on the polymerase chain
reaction (PCR) products. Screening for HBA2/1 gene
deletions was done according to the multiplex gap-PCR
strategy of Tan and coworkers [12] ,w h i l eaP C R -
restriction fragment length polymorphism (RFLP) ap-
proach was used to screen for the commonest point
mutations and small indels in the HBA2/1 genes, leading
to nondeletional α-thalassemia in the Hellenic population
[13].
Electrophoretic mobility shift assays
Electrophoretic mobility shift assays (EMSA) analysis was
performed using total nuclear protein extracts from mouse
erythroleukemia (MEL) and human K562 cells [14]. In
brief, 5 μg nuclear extracts were used per reaction and
competitions were done using 100-fold molar excess of the
indicated double-stranded oligonucleotides before addition
of the nuclear extract. Nucleotide sequence of the oligonu-
cleotides used in these studies is available upon request.
Supershift analysis was performed using a home-brewed
GATA-1 antibody [15, 16].
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levels among the compound heterozygous for the novel HBG2:g.-
109G>T mutation and the silent HBB:g.-101C>T β-thalassemia
mutation (I-3; see also Fig. 1a), and heterozygotes for the silent
HBB:g.-101C>T β-thalassemia mutation (note the markedly increased
Hb F levels in case I-3)
Hematological indices HBB:g.-101C>T
HBG2:g.-109G>T (I-3) Wild-type Wild-type
Females (n=18) Males (n=13)
Age (years)/sex 78/F Adults Adults
Hb (g/dL) 12.1 12.4±1.22 14.5±0.84
Hct (%) 38.5 37.1±2.76 43.1±2.30
RBC (×10
6) 4,440 4,382±446 5,144±265
MCH (pg) 27.3 28.4±1.54 28.5±0.88
MCV (fl) 86.7 85.5±4.03 84.3±2.69
MCHC (%) 31.4 32.7±1.04 33.9±0.64
Hb A2 (%) 4.3 3.79±0.24 3.92±0.37
Hb F (%) 14.3 2.53±1.8 1.60±1.17
Fig. 1 a Family tree showing
the heterozygous and compound
heterozygous cases for the
Hellenic type of nd-HPFH,
bearing the novel HBG2:g.-
109G>T promoter mutation
(depicted in black) and the
HBG2:g.-158C>T polymor-
phism (depicted in light gray)o r
the silent HBB:g.-101C>T β-
thalassemia nonsense mutation
(depicted in dark gray), along
with the corresponding hemato-
logical indices. b Chromatogram
from RP-HPLC from the index
case showing the significant
increase in the Gγ/Aγ-globin
chain ratio
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During routine carrier screening for β-thalassemia, an adult
female subject was identified with moderately elevated Hb
F levels (4.1%) and significantly increased Gγ/Aγ-globin
chain ratio (Fig. 1b). An aberrant electrophoretic pattern
was identified during mutation screening in the HBG2
promoter by DGGE analysis (Fig. 2a). DNA sequencing of
the proximal HBG2 promoter region revealed a novel
sequence variation, namely, a G>T transversion at position
−109 relative to the gene’s transcription initiation site
(HBG2:g.-109G>T; Fig. 2b). DNA sequencing did not
reveal any other variant nucleotide in either one of the γ-
globin genes promoters and distal 5′ regulatory regions
between positions −672 and +25. Neither the HBG2:g.-
158C>T (XmnI) nor the HBG1:g.-225-222(AGCA)del
polymorphisms, which are often correlated with moderately
increased HbF levels, were found in the index case.
Hemoglobin studies and DNA analysis of the available
family members indicated that the propositus mother (I-2)
was a carrier of the HBG2:g.-158C>T (XmnI) polymor-
phism, while both sisters (II-2, II-3) were compound
heterozygotes for the HBG2:g.-158C>T polymorphism
and the novel HBG2:g.-109G>T mutation. Surprisingly, in
the latter cases, Hb F levels were normal. Although the
propositus father was deceased, his sister, who was
available for study, presented with significantly increased
Hb F levels (14.3%; Table 1, Fig. 1a). DNA analysis
revealed that the propositus aunt (I-3) was also compound
heterozygous for the HBG2:g.-109G>T promoter mutation
and the silent HBB:g.-101C>T β-thalassemia mutation. The
HBG2:g.-109G>T base substitution was neither identified
in 31 β-thalassemic chromosomes, bearing the silent
HBB:g.-101C>T mutationnorin209normal(nonthalassemic)
chromosomes, suggesting that the novel HBG2:g.-109G>T
variation is not a frequent polymorphism. Mutation screening
in the HBD gene in the index case and her family members,
using DGGE analysis [11], failed to identify any HBD
mutations (data not shown). In addition, all family members
were not carriers either of known HBA2/1 gene deletions
or the commonest point mutations and small indels in the
HBA2/1 genes, determined by gap-PCR and PCR-RFLP
analysis, respectively.
In order to verify the functional significance of the novel
HBG2:g.-109G>T mutation, we measured Gγ-globin chain
levels, using reverse-phase HPLC. Our results showed that
the Gγ/Αγ-globin chain ratio was significantly increased,
compared to normal (nonthalassemic) individuals and
carriers for the HBB:g.-101C>T mutation (79.2/20.8 versus
40/60, respectively) [17]. Also, we performed EMSA
analysis, using nuclear extracts from both MEL cells and
human K562 cells, expressing the adult and fetal erythroid
program, respectively, in order to assess whether the
HBG2:g.-109G>T mutation affects protein binding in vitro.
Indeed, EMSA analysis using a 40-bp oligonucleotide
bearing the wild-type sequence (G) at position HBG2:g.-
109 showed a double-band electrophoretic pattern, suggest-
ing that two proteins and/or protein complexes bind to the
oligonucleotide used. Addition of nonradioactive GATA-1
oligonucleotides, both from HBG2 and HBB promoters
[15], resulted only in the lower band being efficiently
competed, contrary to the upper band that remained visible
(Fig. 3a), indicating that the lower band most likely
Fig. 2 a DGGE analysis of the promoter region of the HBG2 gene.
Numbering correlates with the family tree in Fig. 1a. Note the mutant
HBG2:g.-158 T (lower band)a n dHBG2:g.-109 T homoduplexes
(upper band) that comigrate in lanes II-2 and II-3, compared to lanes
I-2 and II-1, respectively. The 40–70% denaturing gradient corresponds
to the top and bottom of the gel, respectively. b DNA sequencing
analysis, performed in the forward and reverse (not shown) orientation,
revealing a G>T transition at position −109 of the HBG2 gene promoter
(arrow)
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using GATA-1 antibody, resulting in a supershift of the
lower (GATA-1) band (data not shown). EMSA analysis
using a 40-bp oligonucleotide bearing the mutant sequence
(T) at position HBG2:g.-109 revealed that binding of the
protein (or protein complex) in the upper band was
abolished. These data indicate that the upper band shift
represent protein (or protein complex) binding only to the
wild-type sequence at position HBG2:g.-109 (G) and that
the HBG2:g.-109G>T transversion inhibits protein binding
in vitro. Consistent with previous footprinting experiments
[18], these data suggest that the HBG2:g.-109G>T mutation
is responsible for the resulting nd-HPFH phenotype.
Discussion
In this paper, we report the Hellenic type of nd-HPFH,
resulting from a novel G>T transversion in the promoter
region of the HBG2 gene. In the Hellenic population, the
dominant nd-HPFH is the Greek type (HBG1:g.-117G>A
[6]), accounting for almost 90% of the HPFH chromosomes
[9]. The Cretan nd-HPFH (HBG1:g.-158C>T [9]) is the
second most frequent type, followed by the HBG1:g.-201C>T
and the HBG2:g.-196C>T mutations [19]. No deletional
HPFH has even been reported for the Hellenic population.
The HBG2:g.-109G>T mutation was found both in
heterozygosity as well as in compound heterozygosity with
Fig. 3 a Electrophoretic mobility shift assays of the oligonucleotides
containing either the wild-type (Wt; HBG2:g-109 G) or mutant (Mt;
HBG2:g-109 T) sequence using nuclear protein extracts prepared from
dimethyl sulfoxide-induced MEL cells. The HBG2 −109Mt oligonu-
cleotide most likely abolishes a NF-E3 binding site in vitro (depicted
as two asterisks). Competition with nonlabeled HBG2 −109Wt
oligonucleotide results in the disappearance of GATA-1 and NF-E3
band shifts, suggesting that both proteins bind to the HBG2 −109Wt
oligonucleotide. Competition with nonlabeled HBG2 −567 or HBB
GATA-1 oligonucleotides [15] results in the disappearance only of the
GATA-1 (lower) band. Competition with nonlabeled HBG2 −567 or
HBB GATA-1 oligonucleotides suggests that the affinity of GATA-1 is
stronger to the former oligonucleotide. Use of nuclear protein extracts
prepared from K562 cells yielded identical electrophoretic mobility
shifts (not shown). The asterisk indicates the oligonucleotide sequence
located in the HBB gene promoter region. b Schematic representation
of the various nd-HPFH mutations reported to date for the HBG2 (in
red) and HBG1 (in blue) globin genes (underlined sequences depict
the two small deletions also leading to nd-HPFH). The novel nd-
HPFH mutation reported in this study is highlighted in red. Gray box
represents the sequences downstream to the transcription initiation site
and sequences in solid black boxes represent phylogenetically
conserved fetal globin genes cis-regulatory elements
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HBB:g.-101C>T β-thalassemia mutation, the latter being
one of the most common HBB mutation leading to β-
thalassemia in the Hellenic population [20, 21]. Interest-
ingly, however, the resulting Hb F levels varied in each
case. First of all, heterozygosity for the HBG2:g.-109G>T
mutation resulted in moderately increased Hb F levels in
the index case (4.1%). Also, compound heterozygosity with
the silent HBB:g.-101C>T β-thalassemia mutation resulted
in substantially increased Hb F levels (14.3%), as expected
for compound heterozygous cases for nd-HPFH and β-
thalassemia [22]. There are very few examples of nd-
HPFH/β-thalassemia compound heterozygous cases, which
are extremely rare and only occasionally reported in the
literature [22, 23]. On the contrary, compound heterozygosity
for the HBG2:g.-109G>T mutation and the HBG2:g.-158C>T
polymorphism has no effect in the observed Hb F levels
(Fig. 1a). There are two possible explanations for this
observation: (a) the HBG2:g.-158C>T polymorphism itself
exerts a silencing effect on the HBG2:g.-109G>T mutation or
(b) another yet unidentified cis-regulatory element suppresses
Hb F production in the sisters of the index case. The latter
assumption resembles our recent findings [16] and reaffirms
that the regulation of γ- g l o b i ng e n ee x p r e s s i o na n dH bF
production is multifactorial and likely combinatorial and that
many genetic factors can putatively impact Hb F production
in adults.
The HBG2:g.-109G>T mutation resides at the 3′ end of
the distal HBG2 CCAAT box where the CP1 and NF-E3
transcription factors bind [18]. On the basis of in vitro
binding studies, GATA-1 and NF-E3 have both been
implicated as candidate suppressors of γ-globin gene
transcription that would act by binding to the region [18,
24]. In particular, guanosine at position HBG2:g.-109 has
been previously shown to be a strong contact point for NF-
E3 [24], suggesting that the HBG2:g.-109G>T transversion
activates Hb F production most likely by abolishing NF-E3
binding. This assumption is in accordance with our EMSA
analysis data indicating that the HBG2:g.-109G>T trans-
version results in abolishing protein binding in vitro
(Fig. 3a). Taking into consideration that the Gγ-globin
chain levels were doubled in the index case (I-1; Fig. 1a),
these data strongly suggest that the HBG2:g.-109G>T
mutation is responsible for the resulting HPFH phenotype.
The novel nd-HPFH mutation described in this paper is
located at the 3′ end of the HBG2 gene’s distal CCAAT
box, a phylogenetically conserved cis-regulatory element
that has been shown to harbor many ubiquitous and
erythroid-specific transcription factor binding sites [1].
Nine out of 21 nd-HPFH mutations have been identified
in this region (Fig. 3b), suggesting that this regulatory
element is critical for γ-globin gene transcription. Contrary,
however, to the majority of these nd-HPFH mutations that
have a substantial effect in Hb F production, the HBG2:g.-
109G>T nd-HPFH mutation per se results in only moderate
increase in HbF levels. In addition, the neighboring
HBG2:g.-110A>C mutation, leading to the Czech nd-
HPFH, also has a negligible effect in HbF production
[25]. This is unexpected since the HBG1:g.-117G>A nd-
HPFH mutation, residing at the 5′ end of the distal CCAAT
box, leads to a substantial increase in γ-globin gene
transcription. This can be explained by the fact that (a)
different mutations in the distal CCAAT box abolish
different transcription factors binding [24], which would
exert a differential effect over γ-globin gene reactivation in the
adult stage, (b) the HBG1:g.-117G>A and HBG2:g.-109G>T
reside on different genes, hence their relative distance from
the LCR, being directly proportional to the frequency of
LCR/globin gene promoter interactions [26], varies. It is
noteworthy that not all nd-HPFH mutations give a reproduc-
ible HPFH phenotype in transgenic mice (unpublished data).
Altogether, these data emphasize that γ-globin gene
silencing should be the result of a gradual change in the
transcription factor environment affecting the transcription-
al balance between the HBG1/HBG2 and HBB genes.
Acknowledgements This work was partly supported by grants from
the Greek Ministry of Education (Pythagoras 52211.08) to PK and the
Research Promotion Foundation (Cyprus, ΠΔΕ046_02) and the
European Commission [International Thalassemia Network (ITHANET)
Coordination action 026539] to GPP.
References
1. Stamatoyannopoulos G, Grosveld F (2001) Hemoglobin switching.
In: Stamatoyannopoulos G, Majerus P, Perlmutter R, Varmus H
(eds) Molecular basis of blood diseases, 3rd edn. Saunders,
Philadelphia, pp 135–182
2. Wijgerde M, Grosveld F, Fraser P (1995) Transcription complex
stability and chromatin dynamics in vivo. Nature 377:209–213,
doi:10.1038/377209a0
3. Bollekens JA, Forget BG (1991) Deltabeta thalassemia and
hereditary persistence of fetal hemoglobin. Hematol Oncol Clin
North Am 5:399–422
4. Swank RA, Stamatoyannopoulos G (1998) Fetal gene reactiva-
tion. Curr Opin Genet Dev 8:366–370, doi:10.1016/S0959-437X
(98)80095-6
5. Hardison RC, Chui DH, Giardine B, Reimer C, Patrinos GP,
Anagnou N, Miller W, Wajcman H (2002) HbVar: a relational
database of human hemoglobin variants and thalassemia muta-
tions at the globin gene server. Hum Mutat 19:225–233,
doi:10.1002/humu.10044
6. Gelinas R, Endlich B, Pfeiffer C, Yagi M, Stamatoyannopoulos G
(1985) G to A substitution in the distal CCAAT box of the A
gamma-globin gene in Greek hereditary persistence of fetal
haemoglobin. Nature 313:323–325, doi:10.1038/313323a0
7. Berry M, Grosveld F, Dillon N (1992) A single point mutation is
the cause of the Greek form of hereditary persistence of fetal
haemoglobin. Nature 358:499–502, doi:10.1038/358499a0
8. Patrinos GP, Loutradi-Anagnostou A, Papadakis MN (1995) A
novel DNA polymorphism of the Agamma globin gene
554 Ann Hematol (2009) 88:549–555(Agamma-588 A>G) is linked with the XmnI polymorphism
(Ggamma-158 C>T). Hemoglobin 19:419–423, doi:10.3109/
03630269509005835
9. Patrinos GP, Kollia P, Loutradi-Anagnostou A, Loukopoulos D,
Papadakis MN (1998) The Cretan type of non-deletional
hereditary persistence of fetal hemoglobin [Agamma-158 C>T]
results from two independent gene conversion events. Hum Genet
102:629–634, doi:10.1007/s004390050753
10. Losekoot M, Fodde R, Hartveld CL, van Heeren H, Giordano PC,
Bernini LF (1990) Denaturing gradient gel electrophoresis and
direct sequencing of PCR amplified genomic DNA: a rapid and
reliable diagnostic approach to beta thalassemia. Br J Haematol
76:269–274, doi:10.1111/j.1365-2141.1990.tb07883.x
11. Papadakis MN, Papapanagiotou E, Loutradi-Anagnostou A (1997)
Scanning method to identify the molecular heterogeneity of the
delta-globin gene, especially in delta-thalassemias: detection of
three novel mutations in the promoter region of the gene. Hum
Mutat 9:465–472, doi:10.1002/(SICI)1098-1004(1997)9:5<465::
AID-HUMU14>3.0.CO;2-0
12. Tan AS, Quah TC, Low PS, Chong SS (2001) A rapid and reliable
7-deletion multiplex polymerase chain reaction assay for alpha-
thalassemia. Blood 98:250–251, doi:10.1182/blood.V98.1.250
13. Patrinos GP, van Baal S, Petersen MB, Papadakis MN (2005)
Hellenic National Mutation database: a prototype database for
mutations leading to inherited disorders in the Hellenic popula-
tion. Hum Mutat 25:327–333, doi:10.1002/humu.20157
14. Papachatzopoulou A, Kaimakis P, Pourfarzad F, Menounos PG,
Evangelakou P, Kollia P, Grosveld FG, Patrinos GP (2007)
Increased gamma-globin gene expression in beta-thalassemia
intermedia patients correlates with a mutation in 3′HS1. Am J
Hematol 82:1005–1009, doi:10.1002/ajh.20979
15. Luo HY, Mang D, Patrinos GP, Pourfarzad F, Wuc CJY, Eung SH,
Rosenfield CG, Daoust PR, Braun A, Grosveld FG, Steinberg
MH, Chui DHK (2004) A novel single nucleotide polymorphism
(SNP), T>G, in the GATA site at nucleotide (nt) −567 5′ to the
Ggamma-globin gene may be associated with elevated Hb F.
Blood 104:145a–146a
16. Chen Z, Luo HY, Basran RK, Hsu TH, Mang DW, Nuntakarn L,
Rosenfield CG, Patrinos GP, Hardison RC, Steinberg MH, Chui
DH (2008) A T-to-G transversion at nucleotide −567 upstream of
HBG2 in a GATA-1 binding motif is associated with elevated
hemoglobin F. Mol Cell Biol 28:4386–4393, doi:10.1128/
MCB.00071-08
17. Huisman TH, Harris H, Gravely M, Schroeder WA, Shelton JR,
Shelton JB, Evans L (1977) The chemical heterogeneity of fetal
hemoglobin in normal newborn infants and in adults. Mol Cell
Biochem 17:45–55, doi:10.1007/BF01732554
18. Ronchi AE, Bottardi S, Mazzucchelli C, Ottolenghi S, Santoro C
(1995) Differential binding of the NFE3 and CP1/NFY transcrip-
tion factors to the human gamma- and epsilon-globin CCAAT
boxes. J Biol Chem 270:21934–21941, doi:10.1074/jbc.270.
37.21934
19. Tasiopoulou M, Boussiou M, Sinopoulou K, Moraitis G, Loutradi-
Anagnostou A, Karababa P (2008) (G)gamma-196 C->T, (A)
gamma-201 C->T: two novel mutations in the promoter region of
the gamma-globin genes associated with nondeletional hereditary
persistence of fetal hemoglobin in Greece. Blood Cells Mol Dis
40:320–322, doi:10.1016/j.bcmd.2007.10.007
20. Patrinos GP, Giardine B, Riemer C, Miller W, Chui DH, Anagnou
NP, Wajcman H, Hardison RC (2004) Improvements in the HbVar
human hemoglobin variants and thalassemia mutations for
population and sequence variation studies. Nucleic Acids Res
32:D537–D541, doi:10.1093/nar/gkh006
21. van Baal S, Kaimakis P, Phommarinh M, Koumbi D, Cuppens H,
Riccardino F, Macek M Jr, Scriver CR, Patrinos GP (2007)
FINDbase: a relational database recording frequencies of genetic
defects leading to inherited disorders worldwide. Nucleic Acids
Res 35:D690–D695, doi:10.1093/nar/gkl934
22. Papadakis MN, Patrinos GP, Tsaftaridis P, Loutradi-Anagnostou A
(2002) A comparative study of Greek non-deletional hereditary
persistence of fetal hemoglobin and beta-thalassemia compound hetero-
zygotes. J Mol Med 80:243–247, doi:10.1007/s00109-001-0312-4
23. Kollia P, Kalamaras A, Chassanidis C, Samara M, Vamvakopoulos
NK, Radmilovic M, Pavlovic S, Papadakis MN, Patrinos GP (2008)
Compound heterozygosity for the Cretan type of non-deletional
hereditary persistence of fetal hemoglobin and beta-thalassemia or
Hb Sabine confirms the functional role of the Agamma-158 C>T
mutation in gamma-globin gene transcription. Blood Cells Mol Dis
41:263–264
24. Ronchi A, Berry M, Raguz S, Imam A, Yannoutsos N, Ottolenghi
S, Grosveld F, Dillon N (1996) Role of the duplicated CCAAT
box region in gamma-globin gene regulation and hereditary
persistence of fetal haemoglobin. EMBO J 15:143–149
25. Indrak K, Indrakova J, Kutlar F, Pospisilova D, Sulovska I, Baysal
E, Huisman THJ (1991) Compound heterozygosity for a beta0-
thalassemia (frameshift codons 38/39; −C) and a nondeletional
Swiss type of HPFH (A>C) at NT −110, Ggamma) in a
Czechoslovakian family. Ann Hematol 63:111–115, doi:10.1007/
BF01707283
26. Patrinos GP, de Krom M, de Boer E, Langeveld A, Imam AM,
Strouboulis J, de Laat W, Grosveld FG (2004) Multiple
interactions between regulatory regions are required to stabilize
an active chromatin hub. Genes Dev 18:1495–1509, doi:10.1101/
gad.289704
Ann Hematol (2009) 88:549–555 555